CO5631437A2 - Parecoxib sodico cristalino - Google Patents

Parecoxib sodico cristalino

Info

Publication number
CO5631437A2
CO5631437A2 CO04090186A CO04090186A CO5631437A2 CO 5631437 A2 CO5631437 A2 CO 5631437A2 CO 04090186 A CO04090186 A CO 04090186A CO 04090186 A CO04090186 A CO 04090186A CO 5631437 A2 CO5631437 A2 CO 5631437A2
Authority
CO
Colombia
Prior art keywords
parecoxib
sodium
accordance
sodico
cristalino
Prior art date
Application number
CO04090186A
Other languages
English (en)
Inventor
Ahmad Sheikh
Thomas R Borchardt
Leonard J Ferro
Gerald D Danzer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5631437A2 publication Critical patent/CO5631437A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- El parecoxib sódico en una forma cristalina que es sustancialmente anhidra y sustancialmente no solvatada.2.- El parecoxib sódico de la reivindicación 1 que está en forma A se caracteriza al menos por un patrón de difracción de rayos x en polvo que tiene al menos dos valores 2? seleccionados del grupo formado por 5,6, 9,6, 11,0 y 14,5 ± 0,2 grados.3.- El parecoxib sódico de la reivindicación 1 que está en forma A se caracteriza al menos por un patrón de difracción de rayos x en polvo sustancialmente de acuerdo con la figura 1.4.- El parecoxib sódico de la reivindicación 1 que está en forma A se caracteriza al menos por un espectro de infrarrojos por transformada de Fourier sustancialmente de acuerdo con la figura 2.5.- El parecoxib sódico de la reivindicación 1 que está en forma A se caracteriza al menos por un termograma de calorimetría de barrido diferencial sustancialmente de acuerdo con la figura 3.
CO04090186A 2002-03-15 2004-09-10 Parecoxib sodico cristalino CO5631437A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
CO5631437A2 true CO5631437A2 (es) 2006-04-28

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04090186A CO5631437A2 (es) 2002-03-15 2004-09-10 Parecoxib sodico cristalino

Country Status (18)

Country Link
US (1) US20030232871A1 (es)
EP (1) EP1485362A1 (es)
JP (1) JP2005529084A (es)
KR (1) KR100763045B1 (es)
CN (1) CN1642926A (es)
AR (1) AR038985A1 (es)
AU (1) AU2003220180A1 (es)
BR (1) BR0308431A (es)
CA (1) CA2478500A1 (es)
CO (1) CO5631437A2 (es)
IL (1) IL163780A0 (es)
MX (1) MXPA04008932A (es)
MY (1) MY148518A (es)
NZ (1) NZ535951A (es)
PL (1) PL372880A1 (es)
RU (1) RU2300529C2 (es)
TW (1) TW200400949A (es)
WO (1) WO2003078408A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143431A1 (en) * 2003-04-04 2005-06-30 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
CA2551523A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英（江苏）药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英（江苏）药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN117003769A (zh) * 2023-07-11 2023-11-07 宁波慈溪生物医学工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US7695736B2 (en) * 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
EP1438300A1 (en) * 2001-10-02 2004-07-21 Pharmacia Corporation Method for preparing benzenesulfonyl compounds

Also Published As

Publication number Publication date
RU2004127585A (ru) 2005-04-10
CA2478500A1 (en) 2003-09-25
JP2005529084A (ja) 2005-09-29
CN1642926A (zh) 2005-07-20
KR100763045B1 (ko) 2007-10-04
AR038985A1 (es) 2005-02-02
BR0308431A (pt) 2005-01-18
EP1485362A1 (en) 2004-12-15
RU2300529C2 (ru) 2007-06-10
PL372880A1 (en) 2005-08-08
MXPA04008932A (es) 2004-11-26
IL163780A0 (en) 2005-12-18
TW200400949A (en) 2004-01-16
AU2003220180A1 (en) 2003-09-29
NZ535951A (en) 2006-02-24
MY148518A (en) 2013-04-30
US20030232871A1 (en) 2003-12-18
KR20040095288A (ko) 2004-11-12
WO2003078408A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
CO5631437A2 (es) Parecoxib sodico cristalino
ATE423557T1 (de) Carbocyclische kaliumkanalhemmer
AR077407A2 (es) Forma 5 de efavirenz cristalino, proceso para obtenerla y metodos de uso
DE60112055D1 (de) Inhibitoren von gamma-secretase
MY139235A (en) One step process for the preparation of anticonvulsant derivatives
EP1126849A4 (en) HETEROCYCLIC POTASSIAL CHANNEL INHIBITORS
BR9908701B1 (pt) produto oral para remineralizar dentes.
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
SE0101108D0 (sv) A quaternary ammonium alkyl hydroxyethyl cellulose ether as a conditioner for hair and skin
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
CO4970820A1 (es) Sal de bisulfato del inhibidor de la vih-proteasa
DK0665844T3 (da) Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P
ATE270817T1 (de) Fungizide
NO20033119L (no) Ekspanderbare styrenpolymerer som inneholder karbonpartikler
ATE215978T1 (de) Talkum enthaltende polypropylenzusammensetzungen
DE69928655D1 (de) Substituierte porphyrine
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
ES2167992T3 (es) Composicion de maquillaje que comprende una poli-alfa-olefina.
DE59103664D1 (de) Verfahren zur Inhibierung und Zerstörung von Peroxiden in Dialkylethern.
PT1009436E (pt) Derivado de acridina para aumentar a biodisponibilidade oral do taxol
BR0304213A (pt) Processo para a sìntese industrial de ranelato de estrÈncio e os seus hidratos
DE60129804D1 (de) Hydrophobierende mikro-emulsionen
HUP0000362A2 (hu) Madár-reovírusok új antigén osztálya
CY1112050T1 (el) Νεα 2-αλογονοποιημενα παραγωγα της 5-0- δεσοσαμινυλερυθρονολιδης α, η διαδικασια της παρασκευης τους και η εφαρμογη τους ως φαρμακευτικα προϊοντα
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen

Legal Events

Date Code Title Description
FC Application refused